XBiotech (XBIT)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	183.12 mm	183.12 mm	183.12 mm	183.12 mm	183.12 mm	183.12 mm
Cash burn (monthly)	1.80 mm	1.59 mm	2.63 mm	3.53 mm	1.95 mm	2.32 mm
Cash used (since last report)	9.14 mm	8.05 mm	13.34 mm	17.86 mm	9.87 mm	11.76 mm
Cash remaining	173.98 mm	175.07 mm	169.78 mm	165.26 mm	173.25 mm	171.36 mm
Runway (months of cash)	96.4	110.1	64.4	46.9	88.9	73.8

Beta Read what these cash burn values mean

Financial data from XBiotech earnings reports.

Institutional ownership, Q3 2024

XBIT institutional ownership history Ownership history

18.7% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	51	14	+264.3%
Opened positions	37	4	+825.0%
Closed positions	0	35	EXIT
Increased positions	4	5	-20.0%
Reduced positions	4	1	+300.0%

13F shares	Current	Prev Q	Change
Total value	37.11 bn	4.73 bn	+684.1%
Total shares	5.70 mm	1.78 mm	+219.6%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
BlackRock	1.25 mm	$9.66 bn	NEW
Vanguard	1.06 mm	$8.21 bn	NEW
Bay Street Financial	844.86 k	$13.88 mm	0.0%
Geode Capital Management	452.26 k	$3.50 bn	+5.1%
Millennium Management	281.02 k	$2.17 bn	NEW
Ubs Global Asset Management Americas	253.77 k	$1.96 bn	NEW
STT State Street	224.60 k	$1.74 bn	NEW
NTRS Northern Trust	183.57 k	$1.42 bn	NEW
Bridgeway Capital Management	147.59 k	$1.14 bn	NEW
MS Morgan Stanley	131.69 k	$1.02 bn	NEW

Largest transactions	Shares	Bought/sold	Change
BlackRock	1.25 mm	+1.25 mm	NEW
Vanguard	1.06 mm	+1.06 mm	NEW
Millennium Management	281.02 k	+281.02 k	NEW
Ubs Global Asset Management Americas	253.77 k	+253.77 k	NEW
STT State Street	224.60 k	+224.60 k	NEW
NTRS Northern Trust	183.57 k	+183.57 k	NEW
Bridgeway Capital Management	147.59 k	+147.59 k	NEW
MS Morgan Stanley	131.69 k	+131.69 k	NEW
Charles Schwab Investment Management	58.44 k	+58.44 k	NEW
American Century Companies	130.18 k	+53.72 k	+70.3%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

XBIT insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
31 Jan 25	John Simard	Convertible Loan Agreement Common Shares or Preferred Shares	Other	Dispose J	No	No	4.048001198208355	2,470,355	10.00 mm	870,381
20 Jun 24	W Thorpe Mckenzie	Director Stock Option Common Stock	Grant	Acquire A	No	No	5.12	37,500	192.00 k	37,500
20 Jun 24	Peter Libby	Director Stock Option Common Stock	Grant	Acquire A	No	No	5.12	37,500	192.00 k	37,500
20 Jun 24	Waldin Jan-Paul	Director Stock Option Common Stock	Grant	Acquire A	No	No	5.12	37,500	192.00 k	37,500
20 Jun 24	Donald H. MacAdam	Director Stock Option Common Stock	Grant	Acquire A	No	No	5.12	37,500	192.00 k	37,500

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Press releases

From Benzinga Pro

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT

4 Feb 25

NEW YORK, Feb. 4, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or the "Company") (NASDAQ:XBIT). Such investors are advised to contact

XBIT Investors Have Opportunity to Join XBiotech Inc. Fraud Investigation with the Schall Law Firm

17 Jan 25

LOS ANGELES, Jan.

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating XBiotech for potential violations of securities laws

14 Jan 25

PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION NEW YORK, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights

XBIT Investors Have Opportunity to Join XBiotech Inc. Fraud Investigation with the Schall Law Firm

13 Jan 25

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT

8 Jan 25